Opus Genetics Highlights Strong 2025 Progress, Advances Gene Therapies to Pivotal Trials, and Extends Cash Runway

summarizeSummary

Opus Genetics reported significant progress in its gene therapy pipeline, including advancing a lead program to pivotal Phase 3 and submitting an sNDA for a partnered treatment, while also extending its cash runway into H2 2027.

check_boxKey Events

• Lead Gene Therapy Advances to Pivotal Phase 3

  OPGx-LCA5, a gene therapy for Leber Congenital Amaurosis, is moving into a pivotal Phase 3 trial following positive Phase 1/2 data and multiple FDA designations.

• Key Regulatory Submission for Partnered Product

  A Supplemental New Drug Application (sNDA) was submitted for Phentolamine Ophthalmic Solution 0.75% for presbyopia, with a regulatory decision anticipated by year-end 2026.

• Clinical Progress for OPGx-BEST1

  The OPGx-BEST1 gene therapy program for BEST1-related IRD has dosed its first participant in a Phase 1/2 trial, with initial data expected this quarter and 3-month results in mid-2026.

• Extended Cash Runway

  The company raised approximately $23 million in gross proceeds through a registered direct offering, extending its cash and cash equivalents to over $50 million and funding operations into the second half of 2027.

auto_awesomeAnalysis

Opus Genetics provided a comprehensive update detailing significant advancements across its gene therapy pipeline and a strengthened financial position. The company is progressing two lead ophthalmic gene therapy programs, OPGx-LCA5 and OPGx-BEST1, with OPGx-LCA5 moving into a pivotal Phase 3 trial and OPGx-BEST1 reporting initial Phase 1/2 data soon. Additionally, a Supplemental New Drug Application (sNDA) was submitted for a partnered presbyopia treatment, representing a near-term regulatory catalyst. Financially, a recent $23 million capital raise has extended the company's cash runway into the second half of 2027, providing crucial stability for ongoing operations and development. These milestones collectively indicate strong operational execution and a positive outlook for the company's clinical and financial trajectory.